Description
On the basis of Bevacizumab and an all-human monoclonal antibody B5E3, a two-epitope bispecific antibody Bev-B5E3BsAb targeting VEGF is constructed. Experiments show that the bispecific antibody does not compete with Bevacizumab to combine with VEGF, and it is speculated that the epitopes of the bispecific antibody are new epitopes different from those of Bevacizumab. Meanwhile, compared with two parent monoclonal antibodies of the bispecific antibody, the bispecific antibody can combine with VEGF more effectively. In addition, the bispecific antibody displays stronger ability in inhibiting proliferation of human umbilical vein endothelial cells (HUVEC) in experiments in vitro, animal experiments show that the bispecific antibody can remarkably inhibit growth of tumors. Therefore, the bispecific antibody is expected to be developed into a novel antibody reagent used for treatment or diagnosis of tumors and ophthalmic diseases.
Target
VEGFA
Target Alias Names
Vascular Endothelial Growth Factor A, Vascular Permeability Factor, VEGF, VPF, Vascular Endothelial Growth Factor A121, Vascular Endothelial Growth Factor A165, Vascular Endothelial Growth Factor, VEGF-A, MVCD1
Isotype/Mimetic
Humanized IgG
Animal-Derived Biomaterials Used
None
Sequence Available
No
Original Discovery Method
Human-derived phage display
Original Discovery Information Provided On Datasheet
No
Antibody/Binder Origins
Animal-free discovery, In vitro recombinant expression